Get the Stockscreener App
2.92
19.34%
-0.70
After Hours:
2.89
-0.03
-1.03%
Polaryx Therapeutics Inc stock is traded at $2.92, with a volume of 474.94K.
It is down -19.34% in the last 24 hours and up +0.00% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.
See More
Previous Close:
$3.62
Open:
$3.29
24h Volume:
474.94K
Relative Volume:
22.26
Market Cap:
$138.24M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-81.75%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.80
$5.00
1-Week Range:
$2.80
$17.20
52-Week Range:
$2.80
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare PLYX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.92 | 171.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
Polaryx Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Polaryx to evaluate PLX-200 for Krabbe disease in Phase 2 trial - Investing.com Canada
Polaryx announces pre-clinical data related to Soteria - TipRanks
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ - The Manila Times
In mice with Krabbe disease, Polaryx drug restored movement, extended life - Stock Titan
Dow Falls 250 Points; Becton Dickinson Posts Upbeat Earnings - Benzinga
Morning Market Movers: UOKA, KD, HIMS, PGY See Big Swings - RTTNews
Strategy, Bitmine Immersion Technologies And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Finance Watch: Four IPOs In One Week - Citeline News & Insights
Polaryx appoints Mitchel Berger, Francis Braun, Charles Ryan to board - TipRanks
Polaryx Therapeutics (PLYX) Valuation Check After Sharp Single Day Share Price Decline - simplywall.st
Cerence Inc. (CRNC) - MSN
Eli Lilly and Oracle among market cap stock movers on Thursday - Investing.com
Polaryx Therapeutics, Inc. Announces Board Changes, Effective January 29, 2026 - marketscreener.com
Polaryx Therapeutics Welcomes New Members of the Board of Directors - The Manila Times
Brain tumor director and biotech CEO join Polaryx board as drug enters Phase 2 - Stock Titan
PLYX - Finviz
INTAPP, INC. (INTA) - MSN
Polaryx to present late-breaker data related to Soteria ahead of trial - Yahoo Finance
IBM, Palantir among market cap stock movers on Tuesday By Investing.com - Investing.com Australia
IBM, Palantir among market cap stock movers on Tuesday - Investing.com
FUBOTV INC. (FUBO) Stock, Price, News, Quotes, Forecast and Insights - MSN
GARTNER, INC. (IT) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch - The Manila Times
New Krabbe disease findings support Polaryx’s 4-indication SOTERIA trial - Stock Titan
Why Teradyne Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket - Benzinga
Polaryx Therapeutics Announces to Present Late-Breaker Data Related to Soteria At the 22Nd Annual Worthldsymposium as Company Prepares for Soteria Trial Launch - marketscreener.com
The 4 Biotech Companies on Track to IPO this Week Despite the Government Shutdown - MedCity News
Polaryx Therapeutics, Clinical-Stage Developer of Therapies for Lysosomal Storage Disorders, Files for Nasdaq Capital Market IPO - TradingView
Polaryx announces direct listing on Nasdaq - TipRanks
Polaryx Therapeutics Reports Direct Listing on Nasdaq - marketscreener.com
AQUESTIVE THERAPEUTICS, INC. (AQST) - MSN
Mstone Portfolio Company, Polaryx Therapeutics, Announces Direct Listing on Nasdaq - The Progress Index
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol 'PLYX” - The Manila Times
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX” - marketscreener.com
Rare-disease drug developer Polaryx makes Nasdaq debut today - Stock Titan
Swvl Holdings Corp (SWVL) - MSN
PLYX IPO NewsMicro-cap Polaryx Therapeutics to trade on the Nasdaq today via direct listing - renaissancecapital.com
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq - The Manila Times
Biotech targeting rare pediatric diseases heads to Nasdaq Feb. 2 - stocktitan.net
Skycorp Solar Group Ltd (PN) - MSN
FLYEXCLUSIVE INC. (FLYX) - MSN
Sandhoff Disease Pipeline Analysis Highlights Emerging - openPR.com
DATAVAULT AI INC. (DVLT) Stock, Price, News, Quotes, Forecast and Insights - MSN
DATAVAULT AI INC. (DVLT) - MSN
Evolution Metals & Technologies Corp. (EMAT) - MSN
Uni-Fuels Holdings Limited (UFG) - MSN
Oracle, Nvidia among market cap stock movers on Monday By Investing.com - Investing.com Nigeria
ASCENT SOLAR TECHNOLOGIES, INC. (ASTI) - MSN
Multi Ways Holdings Limited (MWG) - MSN
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
There is no financial data for Polaryx Therapeutics Inc (PLYX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):